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Abstract
Background: Accurate measurement of renal function in cirrhotic patients is still challenging. To find the best test for the
determination of the true glomerular filtration rate (GFR) in cirrhotic patients this study prospectively compared measured
(m)GFR, the gold standard, with estimated (e)GFR using equations based on serum levels of creatinine and cystatin C.
Methods: GFR was measured by sinistrin clearance using the bolus method in 50 patients with cirrhosis (Child Turcotte
Pugh score A, B and C) and 24 age-matched healthy subjects as controls. Measured (m)GFR was compared to eGFR using
bias, accuracy 10 % and 30 %, as well as correlation coefficients.
Results: Creatinine-based equations generally overestimated GFR in patients with cirrhosis and showed a bias (average
difference between mGFR and eGFR) of −40 (CG), −12 (MDRD) and −9 (CKD-EPI-Cr) ml/min/1.73 m2. Cystatin C-based
equations underestimated GFR, especially in patients with Child Turcotte Pugh score C (bias 17 ml/min/1.73 m2for
CKD-EPI-CysC). Of these equations, the CKD-EPI equation that combines creatinine and cystatin C (CKD-EPI-Cr-CysC)
showed a bias of 0.12 ml/min/1.73 m2 as compared to measured GFR.
Conclusions: The CKD-EPI equation that combines serum creatinine and cystatin C measurements shows the best
performance for accurate estimation of GFR in cirrhosis, especially at advanced stages.
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Background
Renal function has a pivotal prognostic value in patients
with cirrhosis [1]. Its critical prognostic impact is indicated
by the inclusion of serum creatinine (Cr) levels in the
widely used MELD (Model for end-stage liver disease)
score, whose value is an accurate predictor of 3-month
mortality in cirrhosis. As a result, the MELD score is widely
used for determining priority for liver transplantation [2].
An accurate evaluation of renal function is of utmost im-
portance in patients with cirrhosis and patients with acute-
on-chronic liver failure, especially those being evaluated for
transplantation. Although the serum level of Cr is an easily
measurable and widely available marker of excretory renal
function, it has limitations in assessing glomerular filtration
rate (GFR) in patients with cirrhosis [3–6]. Due to malnu-
trition, low protein intake, decreased Cr synthesis and in-
creased tubular secretion, GFR in patients with cirrhosis is
overestimated when estimated by serum Cr levels [3]. The
equations that are most frequently used to estimate GFR
include Cockcroft Gault (CG) [7], Modification of Diet in
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Renal Disease (MDRD) [8] and the Chronic Kidney Dis-
ease Epidemiology Collaboration formula (CKD-EPI); these
equations, however, require corrections for age, gender,
ethnicity and body weight. Estimated (e)GFR based on
serum levels of cystatin C (CysC) has been claimed to be
more accurate than Cr-based equations [9, 10]. CysC is a
nonglycosylated low molecular weight protein of the cysta-
tin superfamily of cysteine protease inhibitors [11]. In renal
impairment, its levels increase faster than Cr levels, and
have been considered as valuable for the early detection of
renal dysfunction [12, 13]. Unlike Cr, CysC is independent
of muscle mass, age and gender, and not influenced by
serum bilirubin or malignancy [3, 4, 11, 14]. However,
measurement of CysC, has recently been reported to be
influenced by factors such as low serum albumin levels,
elevated white blood cell count, and elevated CRP levels
[15]. These abnormalities are frequently present in cir-
rhotic patients and consequently are likely to impair
the reliability of CysC-based equations. Therefore, meas-
urement rather than estimation of GFR seems to be
mandatory for these patients.
Although technically demanding, time-consuming and
costly, inulin clearance has been considered the gold
standard for determination of GFR. Inulin is freely fil-
tered by the glomerulus and neither secreted, reab-
sorbed, synthesized nor metabolized by the kidney [16].
In Europe, sinistrin, an inulin-like polyfructosan, exhibit-
ing the same properties as inulin, is preferentially used
for the determination of GFR [17, 18].
The aim of this study was to identify the best equation
for the determination of eGFR in cirrhotic patients with-
out concomitant kidney disease or conditions that are
prone to structural kidney damage (e.g. diabetes). For that
purpose, GFR was determined in 50 cirrhotic patients
using sinistrin clearance measured after single injection
technique (mGFR, measured GFR) and compared to that
estimated by Cr- and CysC-based equations (eGFR). Re-
sults obtained from cirrhotics were compared to those of
healthy controls.
Subjects and methods
Study population and collection of data
This prospective study was performed in accordance with
the Declaration of Helsinki and the applicable laws of the
Republic of Austria in 74 patients referred to our center
between 2012 and 2014. The study protocol was approved
by the ethics committee of the Medical University of Graz
(23–497 ex 10/11). No sample size calculation was done
since this study was performed as a pilot study. To com-
pare different methods of GFR estimation with GFR meas-
urement, 50 patients with compensated or decompensated
cirrhosis of different etiologies as well as 24 age-matched
healthy living kidney donors representing the healthy con-
trol group were included. Patients with known underlying
kidney disease, diabetes, insufficiently treated arterial hyper-
tension, collagen vascular diseases, known malignancy of
the urogenital tract, recurrent urinary tract infections,
ingesting nephrotoxic drugs such as aminoglycosides, or
having a regular intake of non-steroidal anti-inflammatory
drugs were excluded; patients who were pregnant, and/or
breastfeeding and patients being unable to give informed
consent due to cognitive impairment were also excluded.
Patients were recruited during their visit to the liver out-
patient clinic or while being on the inpatient ward. A writ-
ten informed consent was obtained from each patient.
Measurements All investigations for the study took place
at the Department of Nephrology at the Medical Univer-
sity of Graz. After placing a catheter in the antecubital
vein, basement blood samples for serum analyses were
taken. Presence of ascites was determined by abdominal
ultrasound and patients were clinically checked for hep-
atic encephalopathy. Determination of mGFR by sinistrin
clearance was performed using the bolus method, which
has been considered to be advantageous over the continu-
ous infusion since neither urine samples nor steady state
conditions are required [17, 19]. We employed a single-
injection technique with sufficiently long sinistrin serum
concentration contours adapted to a two-compartment
kinetic model with variable parameters for transfer- and
elimination rates, which was extensively described earlier
[18, 20–22]. The computer model used in our study allows
a self-validation of the data that in turn results in GFR
measurements of very high precision [17, 21–23]. Appli-
cation of an exogenous marker performed as single injec-
tion experiment offers the opportunity of exact clearance
determination without potential errors of incorrect steady
state conditions or incomplete urinary collection. Each
study participant received an injection of 2500 mg of sinis-
trin (Inutest®, Fresenius KABI, Graz, Austria) intraven-
ously. Serum concentrations of sinistrin were determined
after 10, 15, 20, 30, 45, 60, 90, 120, 180, 210, 240, and
270 min after injection. An enzymatic method was used
to measure the serum concentration of sinistrin as de-
scribed previously [24]. Cr was measured using a rate-
blanked and compensated modified Jaffé method on a
Cobas analyzer (Roche Diagnostics, Mannheim, Germany).
The Cr assay was standardized by isotope-dilution using
mass spectrometry (ID-MS). Liver tests were measured en-
zymatically and C-reactive protein (CRP) by immunoturbi-
dometry (Roche Diagnostics, Mannheim, Germany). CysC
was determined by particle-enhanced immunonephelome-
try using N Protein Standard UY from Siemens Healthcare
Diagnostics, Marburg, Germany.
Statistical Analysis Measured GFR (mGFR) was com-
pared to eGFR determined by different Cr- and/or CysC-
based equations (CG, MDRD4, Hoek, Larsson, CKD-EPI
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equations using Cr, CysC and both) (Additional file 1). For
calculating the CG equation, the measured body weight of
the patients was used. Agreement between mGFR and
eGFR was assessed using the mean bias (average differ-
ence between mGFR and eGFR), standard error of the
mean bias, the Pearson correlation coefficient and the
concordance correlation coefficient as described previ-
ously [25–27]. Accuracy 10 % and accuracy 30 % of each
equation were calculated [28]. Bland-Altman plots were
prepared showing correlation and mean bias between
mGFR and eGFR [29]. Patients’ characteristics were com-
pared by Student’s T test for continuous variables and
Fisher exact test for categorical ones. Accuracies (P10 and
P30) and correlation coefficients were compared using
McNemar’s test. Statistical analyses were performed using
the commercial software SPSS (IBM SPSS Statistics 21)
and STATA (Stata Statistical Software: Release 13. Stata-
Corp, 2009, College Station, TX, USA).
Results
Patient characteristics and renal function of study cohort
Fifty cirrhotic patients and 24 age-matched healthy liv-
ing kidney donors were studied. Of cirrhotic patients
(78 % males, 22 % females), 18 (36 %) were classified as
Child Turcotte Pugh (CTP) A, 18 as CTP B and 14
(28 %) as CTP C. Alcohol was the main cause of cirrho-
sis (72 %), followed by hepatitis C (8 %) and primary
sclerosing cholangitis (8 %). The mean MELD score was
13 ± 5 (range 7–33). Amongst controls, more than half
of the patients were female (75 %). Liver function in this
group was normal. Patient characteristics are summa-
rized in Table 1. Statistically significant differences be-
tween all cirrhotics and controls were found for total
bilirubin, albumin, prothrombin time, CRP, and CysC
(Table 1). The mean measured (m)GFR amongst all
cirrhotic patients was 89.6 ± 27.5 mL/min/1.73 m2 and
decreased with increasing cirrhosis severity (97.2 ±
24.1 mL/min/1.73 m2 - CTP A, 89.1 ± 25.2 mL/min/
1.73 m2 - CTP B and 80.4 ± 32.8 mL/min/1.73 m2 - CTP
C) (Table 2). Eight patients with cirrhosis had an mGFR
< 60 mL/min/1.73 m2 (Additional file 2). Renal function
in controls and CTP A patients was normal while it was
mildly impaired (mGFR < 90 ml/min/1.73 m2) in cir-
rhotic patients at stage CTP B and C (Table 2).
Performance of Cr-based GFR equations in cirrhosis
Cr-based equations overestimated mGFR in cirrhotic pa-
tients. Amongst all Cr-based equations, the CG equation
showed the highest bias (−40.8 ± 29.2 mL/min/1.73 m2),
followed by MDRD (−11.5 ± 22.0 mL/min/1.73 m2) and
CKD-EPI-Cr (−9.4 ± 20.7 mL/min/1.73 m2). In line with
the high bias, Cr-based equations in cirrhosis showed
low 10 % (P10) and 30 % (P30) accuracies, defined as
percentage of estimates within 10 % and 30 % of mGFR
(4 % and 36 % for CG, 36 % and 74 % for MDRD and
38 % and 78 % for CKD-EPI-Cr). In healthy controls, ac-
curacies of Cr-based equations were higher (Table 2),
with exception of MDRD. Bland-Altman-plots of the
two most commonly used Cr-based equations (MDRD,
CKD-EPI-Cr) compared to mGFR are shown in Fig. 1A.
Performance of CysC-based GFR equations in cirrhosis
In contrast to Cr-based equations, CysC-based equations
underestimated mGFR. Amongst all CysC-based equations,
the Hoek formula had the highest bias (11.1 ± 15.8 mL/
min/1.73 m2), followed by CKD-EPI-CysC (8.2 ± 17.7 mL/
min/1.73 m2) and the Larsson formula (8.1 ± 17.7 mL/min/
1.73 m2). However, compared to Cr-based equations,
CysC-based ones showed a better performance. With re-
spect to P10 and P30, all three formulas were comparable
with 39 % and 84 % for Hoek, 41 % and 82 % for Larsson
and 41 % and 84 % for CKD-EPI-CysC. Underestimation of
mGFR was especially found in CTP C (Table 2).
In controls, the performance of the Hoek, Larsson
and CKD-EPI-CysC equation was not superior to Cr-
based equations. Bias, P10 and P30 of the Hoek and
Larson formula even showed worse performance com-
pared to Cr-based equations and overestimated mGFR.
Bland-Altman-plots comparing the most commonly
used CysC-based equation (CKD-EPI-CysC) to mGFR
are shown in Fig. 1B.
Performance of Cr-based equations decreased with
increasing Child-Turcotte-Pugh Score while performance
of CysC-based equations remained rather constant
By increasing CTP score, performance of Cr-based equa-
tions decreased, showing high biases and low accuracies in
patients with decompensated cirrhosis at stage CTP B and
C (e.g. CKD-EPI-Cr: bias −13.8 ± 20.6 mL/min/1.73 m2,
P10 33 % and P30 78 % for CTP B and bias −12.7 ±
25.4 mL/min/1.73 m2, P10 29 % and P30 57 % for CTP C)
when compared to compensated cirrhotics at stage CTP A
(CKD-EPI-Cr: bias −2.5 ± 15.4 mL/min/1.73 m2, P10 50 %
and P30 94 % for CTP A) (Table 2). Although still overesti-
mating mGFR, the CKD-EPI-Cr formula showed the best
performance amongst all Cr-based equations at advanced
stages of cirrhosis (CTP B and C). Compared to Cr-based
equations, the performance of CysC-based ones was less
influenced by increasing CTP score (e.g. CKD-EPI-CysC:
bias 9.1 ± 12.6 mL/min/1.73 m2 in CTP A; bias 0.8 ±
21.7 mL/min/1.73 m2 in CTP B; bias −17.4 ± 13.5 mL/
min/1.73 m2 in CTP C) (Table 2).
Superiority of the CKD-EPI equation combining Cr and
CysC in patients with cirrhosis
In patients with cirrhosis, the CKD-EPI formula combin-
ing Cr and CysC showed the best performance amongst
all equations. Mean bias was low (0.1 ± 16.3 mL/min/
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Table 1 Characteristics of the study population
Characteristics All Cirrhotics CTP A CTP B CTP C Controls
[N=50] [N=18 (36%)] [N=18 (36%)] [N=14 (28%)] [N=24]
Males/Females 39/11 13/5 ¥ 15/3 & 11/9 6/18¥ &
Age (yrs) 50 ± 9 (24–68) 47 ± 10 (24–67) 51 ± 8 (35–68) 54 ± 8 (36–65) 51 ± 11 (24–66)
BMI (kg/m2) 26 ± 5 (17–40) 25 ± 4 (20–32) 27 ± 6 (17–41) 27 ± 3 (21–34) 25 ± 5 (18–37)
MELD Score 13 ± 5 (7–33) 9 ± 2 (7–13) # 12 ± 2 (8–18) § 19 ± 6 (12–33) # § n.a.
- MELD < 15 38 (76%) 18 (100%) 17 (94%) 3 (21%)
- MELD > 15 12 (24%) 0 (0%) 1 (6%) 11 (79%)
Etiology n.a.
- Alcohol 36 (72%) 10 (56%) 13 (72%) 13 (93%)
- Hepatitis B 1 (2%) 1 (6%) - | -
- Hemochromatosis 1 (2%) 1 (6%) - I -
- PSC 4 (8%) 3 (17%) 1 (6%) | -
- Unknown 1 (2%) - 1 (6%) | -
- AIH 1 (2%) 1 (6%) - 1 -
- Hepatitis C 4 (8%) 1 (6%) 2 (11%) 1 (7%)
- Wilson's disease 2 (4%) 1 (6%) 1 (6%) | -
Ascites n.a.
- None 24 (48%) 17 (94%) % # 6 (33%) % 1 (7%) #
- Mild 11 (22%) 1 (6%) % 8 (44%) % 2 (14%)
- Moderate 15 (30%) - 4 (22%) § 11 (79%) §
Hepatic Encephalopathy n.a.
- None 43 (86%) 18 (100%) 17 (94%) § 8 (57%) §
- Stage I-II 6 (12%) - 1 (6%) 5 (36%)
- Stage III-IV 1 (2%) - - 1 (7%)
Portal Hypertension 46/50 (92%) 14/18 (78%) 18/18 (100%) 14/14 (100%) n.a.
Total Bilirubin (mg/dL) 3.4 ± 6.1 (0.4-36.5)* 1.1 ± 0.6 (0.5-2.6) # 1.9 ± 1.3 (0.4-6.4) § 8.4 ± 10.1 (2.2-36.5) # §$ 0.5 ± 0.2 (0.2-1.5) * $
Albumin (g/dL) 3.6 ± 0.7 (2.3-5.2)* 4.4 ± 0.3 (4.0-5.2)% # 3.4 ± 0.5 (2.8-4.5) % & 3.1 ± 0.5 (2.3-3.8)#$ 4.5 ± 0.4 (3.7-5.2) * &$
Prothrombin Time (%) 62 ±18 (32–104)* 77 ± 14 (52–104)% # ¥ 61 ± 13 (42–88) % §& 45 ± 12(32–73)# §$ 99 ± 10 (72–114) * ¥ & $
CRP (mg/dL) 9 ± 12 (3–70)* 3 ± 3 (3–11) # 9 ± 8 (6–27) 19 ±19(3–70)# $ 2 ± 2 (3–9) * $
Cr (mg/dL) 0.8 ± 0.5-1.6) 0.8 ± 0.2 (0.6-1.4) 0.7 ± 0;2 (0;5–1;1) 0.9 ± 0.3 (0.5-1.6) 0.8: ± 0. 1(0.6–1.0)
CysC (mg/dL) 1.1 ±0.5 (0.6-3.9)* 1.0 ± 0.4 (0.6-2.4) 0.9 ± 0.3 (0.7-1.7) 1.5 ± 0.8 (0.5-3.9) $ 0.7 ± 0.1 (0.5-1.0)* $
Values are expressed as means ± standard deviations or n (%); AIH, autoimmune hepatitis; BMI, body mass index; Cr, Creatinine; CRP, C-reactive protein; CTP, Child-Turcotte-Pugh Score; CysC, Cystatin C; MELD, model
for end-stage liver disease; n.a., not applicable; PSC, primary sclerosing cholangitis. * p <0.05; statistical significant difference between cirrhotics (all) and controls, ** p <0.05; statistical significant difference between CTP
A and CTP B, *** p <0.05; statistical significant difference between CTP A and CTP C, **** p <0.05; statistical significant difference between CTP B and CTP C, ***** p <0.05; statistical significant difference between CTP A












Table 2 Performance of the different eGFR equations
Performance CG MDRD CKD-EPI-Cr Hoek Larsson CKD-EPI CysC CKD-EPI-Cr-CysC
All Cirrhotics [N = 50] mGFR 89.6 ± 27.5
eGFR 130.4 ± 41.0 101.1 ± 26.5 99.0 ± 18.5 78.0 ± 25.8 81.0 ± 31.3 80.9 ± 29.0 89.0 ± 24.8
Bias −40.8 ± 29.2 −11.5 ± 22.0 −9.4 ± 20.7 11.1 ± 15.8 8.1 ± 17.7 8.2 ± 17.7 0.1 ± 16.3
Accuracy 10 % 4 %* 36 % 38 % 39 % 41 % 41 % 49 %
Accuracy 30 % 36 %* 74 % 78 % 84 % 82 % 84 % 84 %
CC (Pearson) (95 % CI) 0.703 (0.52–0.82) 0.688 (0.50–0.81) 0.658 (0.46–0.79) 0.862 (0.77–0.92) 0.826 (0.71–0.89) 0.805 (0.68–0.88) 0.812 (0.69–0.89)
CCC (95 % CI) 0.383* (0.25–0.52) 0.611* (0.45–0.77) 0.563* (0.40–0.72) 0.757 (0.64–0.87) 0.789 (0.68–0.89) 0.771 (0.66–0.88) 0.807 (0.70–0.90)
CTP A [N = 18] mGFR 97.2 ± 24.1
eGFR 126.6 ± 37.9 100.0 ± 26.1 99.7 ± 19.2 83.8 ± 25.2 88.0 ± 31.0 88.1 ± 27.6 93.8 ± 24.6
Bias −29.4 ± 21.6 −2.8 ± 16.1 −2.5 ± 15.4 13.3 ± 12.3 9.2 ± 15.3 9.1 ± 12.6 3.4 ± 11.1
Accuracy 10 % 6 % 61 % 50 % 39 % 44 % 39 % 67 %
Accuracy 30 % 56 % 89 % 94 % 89 % 89 % 94 % 94 %
CC (Pearson) (95 % CI) 0.851 (0.64–0.94) 0.798 (0.53–0.80) 0.771 (0.48–0.91) 0.877 (0.69–0.95) 0.875 (0.69–0.95) 0.889 (0.72–0.96) 0.896 (0.74–0.96)
CCC (95 % CI) 0.529* (0.32–0.74) 0.790 (0.61–0.97) 0.746 (0.54–0.95) 0.785 (0.58–0.93) 0.801 (0.65–0.95) 0.827 (0.69–0.97) 0.887 (0.78–0.99)
CTP B [N = 18] mGFR 89.1 ± 25.2
eGFR 142.7 ± 45.1 106.3 ± 22.7 102.9 ± 13.4 83.2 ± 20.4 86.7 ± 24.7 88.3 ± 25.3 95.4 ± 20.2
Bias −53.7 ± 31.9 −17.2 ± 23.3 −13.8 ± 20.6 5.9 ± 20.1 2.3 ± 21.7 0.8 ± 21.7 −6.3 ± 19.1
Accuracy 10 % 0 % 22 % 33 % 44 % 44 % 44 % 39 %
Accuracy 30 % 28 % 67 % 78 % 83 % 78 % 78 % 78 %
CC (Pearson) (95 % CI) 0.725 (0.39–0.89) 0.534 (0.09–0.80) 0.581 (0.16–0.82) 0.628 (0.23–0.85) 0.623 (0.22–0.84) 0.632 (0.23–0.85) 0.667 (0.29–0.87)
CCC (95 % CI) 0.288 (0.10–0.48) 0.417 (0.10–0.74) 0.387 (0.11–0.66) 0.594 (0.30–0.89) 0.620 (0.32–0.92) 0.631 (0.34–0.93) 0.625 (0.35–0.90)
CTP C [N = 14] mGFR 80.4 ± 32.8
eGFR 119.2 ± 37.9 95.8 ± 31.9 93.1 ± 22.7 62.9 ± 32.8 63.2 ± 35.2 60.5 ± 27.5 73.3 ± 25.6
Bias −38.8 ± 29.4 −15.4 ± 24.8 −12.7 ± 25.4 15.1 ± 12.2 14.7 ± 12.5 17.4 ± 13.5 4.6 ± 16.3
Accuracy 10 % 7 % 21 % 29 % 31 % 31 % 38 % 38 %
Accuracy 30 % 21 % 64 % 57 % 77 % 77 % 77 % 77 %
CC (Pearson) (95 % CI) 0.663 (0.20–0.88) 0.706 (0.28–0.90) 0.635 (0.16–0.87) 0.930 (0.79–0.98) 0.934 (0.80–0.98) 0.915 (0.75–0.97) 0.872 (0.64–0.96)












Table 2 Performance of the different eGFR equations (Continued)
Controls [N = 24] mGF: 97.5 ± 15.1
eGFR 98.7 ± 21.9 85.4 ± 12.9 93.5 ± 12.2 108.4 ± 17.9 118.9 ± 24.1 107.7 ± 13.6 102.1 ± 12.1
Bias −1.2 ± 19.8 12.1 ± 12.3 4.1 ± 10.6 −10.9 ± 19.5 −21.4 ± 24.2 −10.2 ± 12.1 −4.5 ± 9.5
Accuracy 10 % 21 %* 16 %* 54.% 17 %* 37 % 54 % 71 %
Accuracy 30 % 92 % 100 % 100 % 83 % 62 %* 87 % 91 %
CC (Pearson) (95 % CI) 0.481 (0.09–0.74) 0.622 (0.29–0.82) 0.718 (0.44–0.87) 0.314* (−0.10–0.64) 0.303* (−0.11–0.62) 0.649 (0.33–0.83) 0.778 (0.54–0.89)
CCC (95 % CI) 0.449 (0.14–0.80) 0.443 (0.19–0.68) 0.671 (0.46–0.88) 0.252* (−0.06–0.57) 0.171* (−0.06–0.40) 0.510 (0.26–0.76) 0.718 (0.53–0.90)
mGFR and eGFR are expressed as means ± standard deviation in mL/min/1.73 m2; CC, correlation coefficient; CCC, concordance correlation coefficient. * p < 0.05; statistical significant differences between CDK-EPI-Cr-












1.73 m2) and 49 % of estimates were within 10 %, and
84 % were within 30 % of mGFR. Also at advanced stages
of cirrhosis, low biases and high accuracies (bias −6.3 ±
19.1 mL/min/1.73 m2, P10 39 % and P30 78 % in CTP B
and bias 4.6 ± 16.3 mL/min/1.73 m2, P10 38 % and P30
77 % in CTP C) were observed (Table 2). Due to the rela-
tively low number of study patients, statistical significant
differences for P10 and P30 between the CKD-EPI-Cr-
CysC equation and the other equations were only found
for CG (p < 0.0001 for P10 and P30 determined by McNe-
mar’s test, Table 2). Also for correlation coefficients, statis-
tical significant differences between CKD-EPI-Cr-CysC
and all other eGFR equations were only found for Cr-
based equations in all cirrhotics, CG in CTP A and CysC-
based equations in healthy controls. Bland-Altman-plots
comparing mGFR to eGFR determined by the CKD-EPI-
Cr-CysC equation are shown in Fig. 2. Of 50 cirrhotics, 8
had an mGFR < 60 ml/min/1.73 m2 (Additional file 2).
The combined CKD-EPI-Cr-CysC equation correctly
identified 7 out of those 8 patients as patients with im-
paired renal function (eGFR < 60 ml/min/1.73 m2). In con-
trast, less than half of those patients were correctly
identified using Cr-based equations and even a greater pro-
portion of patients were found to have a GFR < 60 ml/min/
1.73 m2 by using CysC-based equations (Additional file 3).
Discussion
There is an urgent need for early and precise detection of
impaired GFR in cirrhotic patients, especially in those suf-
fering from acute on chronic liver failure (ACLF) and being
evaluated for liver transplantation. We, therefore, prospect-
ively evaluated GFR in 50 patients with cirrhosis and 24
healthy controls by measuring the renal function using
sinistrin clearance (mGFR) and comparing its value with es-
timated (e)GFR using creatinine (Cr)- and Cystatin (Cys)C-
based equations. We found that Cr- and CysC-based equa-
tions were inaccurate for the assessment of renal function
in cirrhotic patients. Patients with known renal disease, dia-
betes or nephrotoxic drugs were excluded in order to exclu-
sively study patients with impaired renal function most
likely due to their liver disease. Only by the use of the com-
bined CKD-EPI equation (CKD-EPI-Cr-CysC) we could
obtain results comparable to those measured by sinistrin
clearance. This represents the first prospective study with
direct comparison of several equations for estimating GFR
with the determination of GFR by measurement of sinistrin
clearance using the bolus method.
Due to various limitations (e.g. malnutrition, muscle at-
rophy) the commonly used Cr-based equations for estimat-
ing renal function in cirrhosis are unreliable. Although
having been considered a more sensitive indicator of renal
Fig. 1 a-b. Bland-Altman-plots of eGFR determined by Creatinine (Cr)- and Cystatin C (CysC)-based equations. a Compared to mGFR, the commonly
used Cr-based equations MDRD and CKD-EPI-Cr show less agreement with the gold standard in cirrhotic patients (a, upper panel) as compared to
healthy controls (a, lower panel). b Compared to the Cr-based equations MDRD and CKD-EPI-Cr, the CKD-EPI-CysC equation shows a better performance
in cirrhosis and an almost similar agreement with sinistrin clearance in cirrhotic patients (b, upper panel) and healthy controls (b, lower panel).
a-b Horizontal long-dashed lines depict the bias (average difference between mGFR and eGFR), short-dashed lines show the limits of agreement between
mGFR and eGFR according to the Bland-Altman method, and filled circles denote the measurement points. The oblique straight lines show the regression
line between difference and average, and the shaded areas show the hyperbolic 95 % confidence limits of this regression line. R-values represent the
Pearson’s linear correlation coefficients between difference and average. MDRD, Modification of Diet in Renal Disease; CKD-EPI, Chronic kidney disease
epidemiology collaboration; Cr, Creatinine; CysC, Cystatin C
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function in cirrhosis [25, 30–34], CysC is influenced by fac-
tors independent of GFR which are frequently present in
patients with cirrhosis such as elevated CRP or low serum
albumin levels [15]. Since direct measurement of GFR by
inulin clearance is technically demanding, time-consuming
and costly, easier techniques using synthetic inulin-like
polyfructosans (e.g. sinistrin) have been developed [17, 18].
In contrast to previous studies we determined mGFR by
bolus intravenous injection of sinistrin, a simpler method
without urine collection, which is considered to be more
precise compared to the constant infusion standard
method in healthy subjects and in patients with ascites.
Apart from severity of liver disease, which was less pro-
nounced in our study cohort, patients’ characteristics were
well comparable to previous studies in terms of age, gender
and etiology of cirrhosis. Accordingly, we showed that Cr-
based equations tend to overestimate mGFR and therefore
could not serve as reliable parameters for assessing renal
function in cirrhosis (Table 2). The accordance between
eGFR and mGFR was much better in healthy controls,
although the number of patients in this group was low.
CysC-based equations rather underestimated mGFR in
cirrhosis, however, the performance of these equations
seemed to be less influenced by CTP score and was better
A
B
Fig. 2 Bland-Altman-plots of eGFR determined by the combined CKD-EPI-Cr-CysC equation. Bland-Altman-plots of the CKD-EPI-Cr-CysC equation
compared to mGFR determined by sinistrin clearance show an excellent agreement between eGFR and mGFR for the combined equation. The
agreement between mGFR and eGFR using the combined formula in cirrhotic patients (a) is as good as that in healthy controls (b). a-b Horizontal
long-dashed lines depict the bias (average difference between mGFR and eGFR), short-dashed lines show the limits of agreement between mGFR
and eGFR according to the Bland-Altman method, and filled circles denote the measurement points. The oblique straight lines show the regression
line between difference and average, and the shaded areas show the hyperbolic 95 % confidence limits of this regression line. R-values represent the
Pearson’s linear correlation coefficients between difference and average. CKD-EPI, Chronic kidney disease epidemiology collaboration; Cr, Creatinine;
CysC, Cystatin C
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compared to Cr-based ones, which has as well been con-
firmed by other studies [25, 32]. Although showing a better
performance in accurately assessing mGFR than Cr-based
equations, underestimation of GFR in end-stage cirrhotic
patients by the use of CysC-based equations bears the po-
tential risk of unnecessary simultaneous liver and kidney
transplantation. Amongst all formulas, the CKD-EPI for-
mula combining both, Cr and CysC, showed by far the best
performance in cirrhosis (Table 2). Its diagnostic perform-
ance in cirrhotic patients was even as good as in healthy
subjects and was independent of CTP score (Table 2). We
confirmed the results of a recently published study that
compared the performance of the CKD-EPI-Cr-CysC
equation to mGFR determined by non-radiolabeled iotha-
lamate plasma clearance in cirrhosis and found – similar
to our study - that this equation was superior to other fre-
quently used Cr- and CysC-based equations, although its
performance was still worse than reported by others for
non-cirrhotics [34]. However, measurement of GFR by
renal clearance of iothalamate has been suggested to be
not as accurate as compared to the gold standard inulin or
sinistrin [35]. The performance of the CKD-EPI-Cr-CysC
equation was superior in our study with only 16 % of the
estimated GFR values differing from the mGFR by more
than 30 % in cirrhotic patients (24 % in the study by Mind-
ikoglu et al.) [34]. Our findings of decreasing accuracy of
Cr-based formulas with the increase of CTP score are in
line with results from a study by de Souza et al., who
evaluated a dataset of 202 consecutive liver transplant-
ation candidates. They described a better performance
of CysC-based equations with CKD-EPI-CysC being
considered as the most accurate equation whatever the
magnitude of ascites and even in the presence of sig-
nificant renal dysfunction. However, diabetics were also
included and GFR was measured by the continuous in-
fusion method, which has been reported to be inferior
to the bolus method we used [17, 19, 36].
The main limitation of this study is the number of
study patients that is relatively small. Due to that small
number which was due to careful selection of included
patients, only a few patients appeared to have renal dys-
function and only slight differences in the performance
of CKD-EPI-Cr-CysC as compared to the other CKD-
EPI equations were observed in patients with more ad-
vanced cirrhosis.
Conclusions
We found that Cr-based equations were inaccurate to as-
sess renal function in cirrhosis, in agreement with other
studies [37, 38]. In general, CysC-based equations showed
a better performance than Cr-based ones. Amongst all,
the CKD-EPI equation combining Cr and CysC was su-
perior to other equations in accurately assessing GFR in
cirrhosis. Our results show the utility of cross validation
of different tests to determine renal function in patients
with advanced liver disease.
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